Kazuki Tanaka

Fujieda, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Pulmonary Infarction Secondary to Prostatitis-induced Venous Thromboembolism Mimicking Lobar Pneumonia in a Young Patient: A Diagnostic Pitfall.

Pulmonary Infarction Secondary to Prostatitis-induced Venous Thromboembolism Mimicking Lobar Pneumonia in a Young Patient: A Diagnostic Pitfall.

Journal: Internal medicine (Tokyo, Japan)

Published: May 31, 2026

VEXAS Syndrome with an Improvement of Chest Shadows Without Immunosuppressive Therapy: A Case Report.

VEXAS Syndrome with an Improvement of Chest Shadows Without Immunosuppressive Therapy: A Case Report.

Journal: Internal medicine (Tokyo, Japan)

Published: March 18, 2026

Dual-positive anti-aminoacyl-tRNA synthetase and anti-melanoma differentiation-associated gene 5 antibody-related rapidly progressive interstitial lung disease in a patient with severe coronavirus disease 2019 complicated by probable pulmonary aspergillosis and pneumothorax: a case report.

Dual-positive anti-aminoacyl-tRNA synthetase and anti-melanoma differentiation-associated gene 5 antibody-related rapidly progressive interstitial lung disease in a patient with severe coronavirus disease 2019 complicated by probable pulmonary aspergillosis and pneumothorax: a case report.

Journal: BMC pulmonary medicine

Published: February 19, 2026

Geriatric nutritional risk index in antifibrotic therapy can predict tolerability and mortality risk.

Geriatric nutritional risk index in antifibrotic therapy can predict tolerability and mortality risk.

Journal: Scientific reports

Published: January 14, 2026

Pretreatment clinical and hematological predictors of efficacy and immune-related adverse events in patients with advanced non-small cell lung cancer receiving first-line chemotherapy combined with immune checkpoint inhibitors.

Pretreatment clinical and hematological predictors of efficacy and immune-related adverse events in patients with advanced non-small cell lung cancer receiving first-line chemotherapy combined with immune checkpoint inhibitors.

Journal: BMC cancer

Published: November 20, 2025

Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study.

Peripheral blood UBA1 variant burden predicts poor outcomes in VEXAS syndrome: a nationwide prospective study.

Journal: Annals of the rheumatic diseases

Published: October 27, 2025

Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials.

Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials.

Journal: BMC cancer

Published: February 14, 2025

Diagnostic Challenge and Treatment Delay in Drowning-Associated Pneumonia: A Case of Combined Aeromonas, Legionella, and Aspergillus Infection.

Diagnostic Challenge and Treatment Delay in Drowning-Associated Pneumonia: A Case of Combined Aeromonas, Legionella, and Aspergillus Infection.

Journal: Case reports in infectious diseases

Published: September 24, 2024

Low remission rates and high incidence of adverse events in a prospective VEXAS syndrome registry.

Low remission rates and high incidence of adverse events in a prospective VEXAS syndrome registry.

Journal: Rheumatology (Oxford, England)

Published: July 11, 2024

Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.

Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 04, 2024

The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer.

The Prognostic Nutritional Index before durvalumab after chemoradiation predict the overall survival in patients with stage III non-small cell lung cancer.

Journal: Annals of medicine

Published: April 12, 2023

Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.

Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.

Journal: BMC cancer

Published: October 28, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026